BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 8156482)

  • 21. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Liaros A; Athanassiou E; Dombros N; Dervenis C; Basdanis G; Gamvros O; Souparis A; Briasoulis E; Samantas E; Kappas A; Kosmidis P; Skarlos D; Pavlidis N
    Ann Oncol; 1999 Jun; 10(6):671-6. PubMed ID: 10442189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
    Hudes GR; Lipsitz S; Grem J; Morrisey M; Weiner L; Kugler JW; Benson A
    Cancer; 1999 Jan; 85(2):290-4. PubMed ID: 10023694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
    Yang TS; Wang JY; Tang R; Hsu KC; Chen JS
    Jpn J Clin Oncol; 2002 Sep; 32(9):352-7. PubMed ID: 12417601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
    Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
    Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
    Cassano A; Pozzo C; Corsi DC; Fontana T; Noviello MR; Astone A; Barone C
    J Cancer Res Clin Oncol; 1995; 121(8):474-7. PubMed ID: 7642690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
    Comella P; De Vita F; De Lucia L; Casaretti R; Avallone A; Orditura M; Rivellini F; Palmeri S; Catalano G; Comella G
    Ann Oncol; 2000 Apr; 11(4):461-8. PubMed ID: 10847467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
    Tsavaris N; Gennatas K; Kosmas C; Skopelitis HM; Gouveris P; Dimitrakopoulos A; Zacharakis M; Kouraklis G; Vasiliou J; Felekouras E; Voros D; Zografos G; Balafouta M; Paraskevaidis M; Safioleas M; Fotiadis K; Papastratis G; Karatzas G; Papalambros E
    Oncol Rep; 2004 Oct; 12(4):927-32. PubMed ID: 15375524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
    Bertrand M; Doroshow JH; Multhauf P; Blayney DW; Carr BI; Cecchi G; Goldberg D; Leong L; Margolin K; Metter G
    J Clin Oncol; 1986 Jul; 4(7):1058-61. PubMed ID: 3487626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
    O'Connell MJ; Klaassen DJ; Everson LK; Cullinan S; Wieand HS
    NCI Monogr; 1987; (5):185-8. PubMed ID: 3501540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.